A series of studies indicate that overexpression of MDM2 in tumors correlates with a poor prognosis for these cancer patients [16], and high MDM2 expression occurs more frequently in metastatic and recurrent cancers than in primary tumors [17]. The gene discussed is MDM2; the disease is cancer.